deltatrials
Completed PHASE1/PHASE2 NCT01335685

Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma

An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment

Sponsor: Millennium Pharmaceuticals, Inc.

Conditions Multiple Myeloma
Interventions Ixazomib Melphalan Prednisone
Updated 11 times since 2017 Last updated: Dec 22, 2017 Started: Jun 27, 2011 Primary completion: Dec 29, 2016 Completion: Dec 29, 2016

A PHASE1/PHASE2 clinical study on Multiple Myeloma, this trial is completed. The trial is conducted by Millennium Pharmaceuticals, Inc. and has accumulated 11 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

11 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Mar 2022 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2022 — Mar 2022 [monthly]

    Completed PHASE1_PHASE2

▶ Show 6 earlier versions

  1. Jan 2021 — Jan 2022 [monthly]

    Completed PHASE1_PHASE2

  2. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  3. Feb 2018 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  4. Mar 2017 — Feb 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Feb 2017 — Mar 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Millennium Pharmaceuticals, Inc.
Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Badalona, Spain, Barcelona, Spain, Bournemouth, United Kingdom, Brighton, United Kingdom, Brno, Czechia, Cambridge, United Kingdom, Donostia / San Sebastian, Spain, Lebanon, United States, London, United Kingdom, Madrid, Spain and 10 more location s